Oxurion Receives EUR 1.0 Million under Amended Atlas Funding Program   Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Reach…


Leuven, BELGIUM, Boston, MA, US – November 16, 2023 – 7 pm CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced today that it has received EUR 1.0 million in funding under the Subscription Agreement with Atlas Special Opportunities LLC (“Atlas”).

Continued here:
Oxurion Receives EUR 1.0 Million under Amended Atlas Funding Program   Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Reach...

Related Posts